Antisoma to evaluate rainforest anti-cancer compounds from EcoBiotics Ltd
Antisoma plc and EcoBiotics Ltd, a privately held drug discovery company based in Australia, announced the signature of an agreement under which Antisoma will evaluate and have an option to license early-stage anti-cancer compounds from EcoBiotics. Antisoma will choose up to three compounds from the EcoBiotics portfolio to evaluate during the next year. If these evaluations yield positive results, Antisoma will have rights to license up to two of the compounds for development as anti-cancer drugs on pre-agreed terms.
EcoBiotics has a diverse portfolio of structurally defined and patent-protected molecules derived from tropical rainforest plants. A number of these molecules have already demonstrated anti-cancer activity in early preclinical assessments. All those evaluated by Antisoma will be small molecules that can be made by chemical synthesis.
Other news from the department business & finance
